Lithuania-based startup BrachyDOSE, which helps hospitals reduce radiotherapy costs and prevent radiation-induced injuries, has secured €50,000 from the Estonian Business Angels Network at the sTARTUp Day 2025 Pitching Competition. Additionally, the startup received €3,000 in legal services from Sorainen.
- Founded in 2024 by Neringa Šeperienė and Rimas Šeperys, BrachyDOSE develops an advanced quality control tool for cancer treatment, combining hardware and AI-driven software to enhance radiotherapy accuracy.
- The system includes a disposable flexible-tube sensor, a scanner, and a machine learning-powered injury prediction algorithm. Before treatment, the sensor is placed near the tumor to measure radiation in real-time.
- After the procedure, collected data is analyzed to detect dose discrepancies and predict potential side effects.
- The startup claims its solution saves 50% of medical personnel’s time, shortens hospital stays by 3–5 days, and reduces treatment costs by up to five times.
Details of the deal
- The investment came from the Estonian Business Angels Network (EstBAN), a Tallinn-based firm that connects investors with early-stage startups, fostering seed investments and collaboration. The startup was also awarded €3,000 in legal services from Sorainen.
- BrachyDOSE will use the funding to advance its AI-powered technology, support clinical trials, and scale production. The legal services will help with compliance and IP protection, accelerating the startup’s mission to improve brachytherapy and patient outcomes.
"This recognition and support is a huge boost for our team, and we are incredibly grateful for the trust and confidence placed in us. These investments will help accelerate our mission to innovate and improve the future of brachytherapy, transforming healthcare for patients worldwide," BrachyDOSE's team, commented on LinkedIn.
